Coloplast A/S - Interim Financial Report, Q1 2023/24 - Seite 2

• The organic revenue growth is still expected around 8% and continues to assume good momentum across business areas and regions. Reported growth in DKK is now expected to be around 11%, from previously around 12%, and assumes around 1%-point negative impact from currencies, mostly the USD and ARS. The impact from the acquisition of Kerecis to reported growth is still expected around 4%-points (11 months).
• The reported EBIT margin before special items is still expected to be 27-28%. The EBIT margin includes around 100 basis points dilution from Kerecis (incl. around DKK 100 million in PPA amortisation) and negative impact from currencies.
• Capital expenditures are still expected around DKK 1.4 billion. The effective tax rate is still expected to be around 22%.

“We deliver a good start to the year with 8% organic growth and a 28% EBIT margin in Q1, which is in line with our financial guidance. I want to highlight a strong first quarter in our Chronic Care business, which delivered broad-based growth, as well as a good start to the year for our newest member of the Coloplast family, Kerecis. I am also pleased with our profitability performance in Q1. Finally, we have now kicked off a year of product launches that will help drive our future growth. This quarter, we are launching Biatain Silicone Fit for pressure injury prevention and wound management in the US, as well as Peristeen Light for people with bowel disorders in Europe. I believe both products will make a significant difference to people living with intimate healthcare needs,” says Kristian Villumsen, President and CEO of Coloplast.

^{_{1) before special items of DKK 15 million in Q1 2023/24
2) before special items of DKK 13 million in Q1 2022/23}}

Conference call

Coloplast will host a conference call on Friday, 9 February 2024 at 11.00 CET. The call is expected to last about one hour.
To actively participate in the Q&A session please sign up ahead of the conference call on the link here to receive an e-mail with dial-in details: Register here
Access the conference call webcast directly here: Coloplast - Q1 2023/24 conference call

 

For further information, please contact

Investors and analysts
Anders Lonning-Skovgaard
Executive Vice President, CFO
Tel. [phone]

Aleksandra Dimovska
Senior Director, Investor Relations
Tel. [phone]
Email: [e-mail]

Kristine Husted Munk
Senior Manager, Investor Relations
Tel. [phone]
Email: [e-mail]